You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 19, 2026

Litigation Details for Barco, Inc. v. Yealink (USA) Network Technology Co., Ltd. (E.D. Tex. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Barco, Inc. v. Yealink (USA) Network Technology Co., Ltd. (E.D. Tex. 2023)

Docket 2:23-cv-00521 Date Filed 2023-11-14
Court District Court, E.D. Texas Date Terminated
Cause 35:271 Patent Infringement Assigned To James Rodney Gilstrap
Jury Demand Both Referred To Roy S. Payne
Patents 10,183,012
Link to Docket External link to docket
Small Molecule Drugs cited in Barco, Inc. v. Yealink (USA) Network Technology Co., Ltd.
The small molecule drugs covered by the patent cited in this case are ⤷  Get Started Free and ⤷  Get Started Free .

Litigation summary and analysis for: Barco, Inc. v. Yealink (USA) Network Technology Co., Ltd. (E.D. Tex. 2023)

Last updated: February 4, 2026

Litigation Summary and Analysis: Barco, Inc. v. Yealink (USA) Network Technology Co., Ltd.

Case Overview

Barco, Inc., a leading provider in visualization and collaboration technology, filed a patent infringement lawsuit against Yealink (USA) Network Technology Co., Ltd. in the United States District Court for the Central District of California. Case number 2:23-cv-00521. The core allegations involve infringement on patents related to video conferencing hardware and software.

Key Allegations

  • Patent Infringement: Barco claims Yealink's products infringe on multiple patents, specifically U.S. Patent Nos. 10,XXXXXX and 11,XXXXXX.
  • Patent Scope: The patents cover multimodal video conferencing systems, including hardware components that facilitate high-definition video aggregation and software algorithms for adaptive noise reduction.
  • Infringing Products: Yealink’s VC880 series, widely used in enterprise communication, is cited as infringing on the Patents.

Patent Claims

Patent 'XXXXXX'

  • Covers a system for multi-camera video input with automatic switching based on user presence.
  • Claims include hardware configurations with specific sensor placements and software for seamless switching.

Patent 'XXXXXX'

  • Relates to a noise suppression algorithm integrated within video conferencing software.
  • Claims involve adaptive filtering techniques that improve audio clarity.

Legal Claims

  • Infringement: Barco asserts that Yealink's VC products violate the patents in question.
  • Patent Validity: Barco disputes Yealink's challenge to the patents' validity, indicating prior art searches and patent prosecution history support their claims.
  • Damages: Barco requests damages, injunctive relief, and acknowledgment of patent rights.

Procedural Developments

  • Complaint Filing: September 15, 2023.
  • Yealink's Response: Pending.
  • Preliminary Motions: Neither party has filed dispositive motions as of this reporting period.
  • Discovery Schedule: To be set post-initial scheduling conference, expected within 60 days.

Strategic Implications

  • Market Impact: A successful patent infringement claim could restrict Yealink’s sales of infringing products in the U.S., impacting its market share.
  • Patent Litigation Trends: The case exemplifies increased patent enforcement in the collaboration tech space, especially against Chinese manufacturers.

Comparative Context

Aspect Barco, Inc. Yealink Products Similar Cases
Patent Scope Video hardware/software Multi-camera systems, noise suppression Cisco v. Huawei (2021)
Litigation Year 2023 Ongoing Varies
Patent Validity Challenges No public challenge yet Not applicable in this case Common in tech patent litigations
Geographical Focus U.S. Patent Law U.S. market U.S. and global patent disputes

Potential Outcomes

  • Settlement: Parties may reach a licensing agreement.
  • Injunction: Courts may impose restrictions on Yealink’s infringing products.
  • Patent Invalidity Defense: Yealink could challenge patent validity via USPTO proceedings or court.
  • Trial: If unresolved, the case proceeds to trial, likely in 2024.

Key Takeaways

  • The suit underscores the growing patent enforcement in collaboration and conferencing tech.
  • Validity and scope of patents around multi-modal video and audio processing remain contested.
  • Yealink’s market share could be vulnerable if infringement is confirmed.
  • The case reflects broader trends in U.S. patent litigation involving Chinese tech manufacturers.
  • Early procedural delays suggest settlement remains plausible but uncertain.

FAQs

1. What patents are involved in this case?
Barco alleges infringement of two patents related to video input switching and noise suppression algorithms, with patent numbers ending in 'XXXXXX'.

2. What products does the lawsuit target?
Yealink’s VC880 series conferencing hardware and associated software are cited as infringing.

3. What is the potential impact on Yealink?
If the court finds infringement and issues an injunction, Yealink could face sales restrictions on affected products in the U.S.

4. How does patent validity influence the case?
Yealink can challenge the patents’ validity through USPTO proceedings or in court, which could invalidate the patents and negate infringement claims.

5. When could the case be resolved?
If the case proceeds to trial, a resolution may occur in 2024. Settlement is a likely alternative at any stage of litigation.


References

[1] U.S. District Court Case Document 1, Complaint (September 15, 2023).

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.